Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ EVIVE Biotechnology
EVIVE Biotechnology
Industry · 11 registered clinical trials.
Status
Trial
Phase
Started
Withdrawn
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
COVID-19 Pneumonia
Phase 2
2022-04-08
Terminated
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Covid19
Phase 2
2021-01-26
Unknown
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Relapsed or Refractory B-cell Lymphoma
Phase 1
2019-09-15
Completed
Study to Compare the Efficacy and Safety of F-627 and GRAN®
Breast Cancer, Neutropenia
Phase 3
2018-04-12
Completed
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer, Neutropenia
Phase 3
2018-04-12
Completed
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer, Neutropenia
Phase 3
2016-08-01
Completed
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Acute Graft vs Host Disease
Phase 1 / Phase 2
2016-05-12
Completed
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Neutropenia
Phase 2
2014-07-03
Completed
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Neutropenia
Phase 1 / Phase 2
2014-02-25
Completed
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Neutropenia, Breast Cancer
Phase 1
2012-12-01
Completed
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer, Neutropenia
Phase 2
2012-06-01